Susana Barriga

5.9k total citations · 4 hit papers
26 papers, 3.7k citations indexed

About

Susana Barriga is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Susana Barriga has authored 26 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Susana Barriga's work include Advanced Breast Cancer Therapies (22 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer-related Molecular Pathways (7 papers). Susana Barriga is often cited by papers focused on Advanced Breast Cancer Therapies (22 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer-related Molecular Pathways (7 papers). Susana Barriga collaborates with scholars based in United States, Spain and Japan. Susana Barriga's co-authors include Masakazu Toi, Martin Frenzel, Joohyuk Sohn, Nawel Bourayou, Matthew P. Goetz, Norikazu Masuda, Tammy Forrester, George W. Sledge, Angelo Di Leo and Peter A. Kaufman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Susana Barriga

25 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. JAMA Oncology profile →
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

2019 407 citations Stephen Johnston, Miguel Martín et al. npj Breast Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susana Barriga United States	13	3.3k	2.9k	1.2k	920	279	26	3.7k
Martin Frenzel United States	14	3.7k 1.1×	3.2k 1.1×	1.3k 1.1×	998 1.1×	402 1.4×	28	4.1k
Han Koh United States	12	1.9k 0.6×	2.2k 0.8×	866 0.7×	529 0.6×	304 1.1×	27	2.8k
Janice M. Walshe Ireland	19	2.1k 0.6×	2.5k 0.9×	1.2k 0.9×	514 0.6×	414 1.5×	69	3.4k
Nawel Bourayou United States	9	2.1k 0.6×	1.9k 0.6×	750 0.6×	560 0.6×	203 0.7×	25	2.4k
Kathy Puyana Theall United States	9	2.1k 0.6×	1.9k 0.7×	814 0.7×	550 0.6×	286 1.0×	26	2.4k
Meena Okera Australia	12	1.7k 0.5×	1.5k 0.5×	640 0.5×	492 0.5×	204 0.7×	32	2.0k
Olga Burdaeva Russia	12	1.7k 0.5×	1.6k 0.6×	640 0.5×	465 0.5×	225 0.8×	27	2.1k
Katarína Petráková Czechia	23	1.4k 0.4×	2.1k 0.7×	989 0.8×	301 0.3×	645 2.3×	66	2.8k
Eva Ciruelos Spain	15	1.4k 0.4×	1.5k 0.5×	936 0.8×	399 0.4×	924 3.3×	76	2.5k

Countries citing papers authored by Susana Barriga

Since Specialization

Citations

This map shows the geographic impact of Susana Barriga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susana Barriga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susana Barriga more than expected).

Fields of papers citing papers by Susana Barriga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susana Barriga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susana Barriga. The network helps show where Susana Barriga may publish in the future.

Co-authorship network of co-authors of Susana Barriga

This figure shows the co-authorship network connecting the top 25 collaborators of Susana Barriga. A scholar is included among the top collaborators of Susana Barriga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susana Barriga. Susana Barriga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Timothy A., Minal Barve, E.P. Hamilton, et al.. (2025). 924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors. Annals of Oncology. 36. S566–S567. 1 indexed citations

Simonelli, Matteo, Emiliano Calvo, Diwakar Davar, et al.. (2022). Abstract CT119: A randomized, double-blind phase 2 evaluation of the anti-IL-8 monoclonal antibody BMS-986253 + nivolumab + ipilimumab vs nivolumab + ipilimumab in patients with advanced melanoma that progressed on/after anti-PD-(L)1 therapy. Cancer Research. 82(12_Supplement). CT119–CT119.

Harbeck, Nadia, Stephen Johnston, Peter A. Fasching, et al.. (2021). Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. Cancer Research. 81(4_Supplement). PD2–1. 11 indexed citations

Rugo, Hope S., Jens Huober, José Á. García-Sáenz, et al.. (2020). Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. The Oncologist. 26(1). e53–e65. 105 indexed citations

Hurvitz, Sara A., Miguel Martín, Michael F. Press, et al.. (2019). Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer. Clinical Cancer Research. 26(3). 566–580. 154 indexed citations

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2019). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2. JAMA Oncology. 6(1). 116–116. 590 indexed citations breakdown →

Johnston, Stephen, Miguel Martín, Angelo Di Leo, et al.. (2019). MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer. 5(1). 5–5. 407 indexed citations breakdown →

Neven, Patrick, Hope S. Rugo, Sara M. Tolaney, et al.. (2018). Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1002–1002. 13 indexed citations

Martín, Miguel, SA Hurvitz, Ding‐Cheng Chan, et al.. (2018). Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC). Cancer Research. 78(4_Supplement). PD5–1. 21 indexed citations

10.

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →

11.

Goetz, Matthew P., Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology. 35(32). 3638–3646. 1125 indexed citations breakdown →

12.

Guarneri, Valentina, Peter A. Fasching, José Á. García-Sáenz, et al.. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer. Annals of Oncology. 28. vi25–vi25. 1 indexed citations

13.

Hurvitz, Sara A., Miguel Martín, Ding‐Cheng Chan, et al.. (2017). Abstract S4-06: Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer. Cancer Research. 77(4_Supplement). S4–6. 12 indexed citations

14.

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Journal of Clinical Oncology. 35(15_suppl). 1000–1000. 10 indexed citations

15.

Leo, Angelo Di, Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Annals of Oncology. 28. v609–v609. 13 indexed citations

16.

Iwata, Hiroji, Petros Nikolinakos, J. Thaddeus Beck, et al.. (2017). Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2. Annals of Oncology. 28. v81–v82. 1 indexed citations

17.

Tolaney, Sara M., et al.. (2017). Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC). Cancer Research. 77(4_Supplement). P6–15. 7 indexed citations

18.

Hurvitz, Sara A., Ding‐Cheng Chan, Daniel Egle, et al.. (2016). breast cancer, early stage Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC). Annals of Oncology. 27. vi552–vi552. 16 indexed citations

19.

Barriga, Susana, Fátima Rodrigues, & Cristina Bárbara. (2014). Factors that influence physical activity in the daily life of male patients with chronic obstructive pulmonary disease. Revista Portuguesa de Pneumologia. 20(3). 131–137. 23 indexed citations

20.

Lal, Rohit, Nawel Bourayou, Gunnar Hillerdal, et al.. (2013). Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health and Quality of Life Outcomes. 11(1). 163–163. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact